Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
AKTX — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

1.44

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

-8.01

EPS This/Next Y

6.73

Price

7.61

Target Price

30

Analyst Recom

1

Performance Q

6.38

Upside

-9,530.0%

Beta

1.39

Ticker: AKTX




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-07-14AKTX13.20.090.00151
2026-07-15AKTX12.070.080.00155
2026-07-16AKTX11.460.080.00155
2026-07-17AKTX110.080.00155
2026-07-20AKTX10.810.000.00162
2026-07-21AKTX9.160.000.00168
2026-07-22AKTX9.560.000.00189
2026-07-23AKTX9.130.000.00194
2026-07-24AKTX8.50.000.00194
2026-07-27AKTX8.270.000.00194
2026-07-28AKTX8.250.000.00194
2026-07-29AKTX8.190.000.00195
2026-07-30AKTX7.810.000.00196
2026-07-31AKTX7.80.000.00196
2026-08-03AKTX7.190.000.00201
2026-08-04AKTX7.870.000.00201
2026-08-05AKTX7.250.000.00201
2026-08-06AKTX8.080.000.00201
2026-08-07AKTX7.220.000.00201
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-07-14AKTX13.16- - -2.88
2026-07-15AKTX12.05- - -2.88
2026-07-16AKTX11.50- - -2.88
2026-07-17AKTX11.00- - -2.88
2026-07-20AKTX10.82- - -2.88
2026-07-21AKTX9.24- - -2.88
2026-07-22AKTX9.70- - -2.88
2026-07-23AKTX9.55- - -2.88
2026-07-24AKTX8.69- - -8.01
2026-07-27AKTX8.51- - -8.01
2026-07-28AKTX8.44- - -8.01
2026-07-29AKTX8.24- - -8.01
2026-07-30AKTX7.80- - -8.01
2026-07-31AKTX7.94- - -8.01
2026-08-03AKTX7.35- - -8.01
2026-08-04AKTX7.35- - -8.01
2026-08-05AKTX7.55- - -8.01
2026-08-06AKTX8.09- - -8.01
2026-08-07AKTX7.61- - -8.01
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-07-14AKTX0.0050.131.58
2026-07-15AKTX0.0050.131.58
2026-07-16AKTX0.0050.131.58
2026-07-17AKTX0.0050.131.58
2026-07-20AKTX0.0050.131.58
2026-07-21AKTX0.0050.131.58
2026-07-22AKTX0.0050.131.58
2026-07-23AKTX0.0050.131.58
2026-07-24AKTX0.0050.131.58
2026-07-27AKTX0.0034.851.44
2026-07-28AKTX0.0034.851.44
2026-07-29AKTX0.0034.851.44
2026-07-30AKTX0.0034.851.44
2026-07-31AKTX0.0034.851.44
2026-08-03AKTX0.0034.851.44
2026-08-04AKTX0.0034.851.44
2026-08-05AKTX0.0034.851.44
2026-08-06AKTX0.0034.851.44
2026-08-07AKTX0.0034.851.44
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-1.04

Avg. EPS Est. Next Quarter

-1.08

Insider Transactions

Institutional Transactions

34.85

Beta

1.39

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

10

Growth Score

17

Sentiment Score

31

Actual DrawDown %

99.5

Max Drawdown 5-Year %

-99.8

Target Price

30

P/E

Forward P/E

PEG

P/S

P/B

0.56

P/Free Cash Flow

EPS

-18.86

Average EPS Est. Cur. Y​

-8.01

EPS Next Y. (Est.)

-1.28

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.03

Return on Equity vs Sector %

-100

Return on Equity vs Industry %

-100

EPS 1 7Days Diff

-5.1

EPS 1 30Days Diff

-5.13

EBIT Estimation

AKTX Healthcare
$7.00
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
6/20
Pullback
17/25
Volume
11/15
Valuation
12/20
TP/AR
6/10
Options
7/10
RSI
35.2
Range 1M
2.7%
🚀
Momentum Growth
Ride accelerating trends
N/A
41 /100
WEAK
Momentum
3/25
Growth
18/30
Estimates
6/20
Inst/Vol
6/15
Options
8/10
EPS Yr
61.3%
EPS NY
68%
52W%
9.4%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +328.6% upside
Quality
2/30
Valuation
16/30
Growth
14/25
Stability
5/10
LT Trend
4/5
Upside
+328.6%
Quality
10
AKTX — P/E HistoricalBiotechnology
Akari Therapeutics Plc
Sector: Healthcare
Industry: Biotechnology
Employees: 5
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
AKTX

Latest News

Caricamento notizie per AKTX
stock quote shares AKTX – Akeso Inc. Stock Price stock today
news today AKTX – Akeso Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch AKTX – Akeso Inc. yahoo finance google finance
stock history AKTX – Akeso Inc. invest stock market
stock prices AKTX premarket after hours
ticker AKTX fair value insiders trading